Arch Biopartners Inc
🇨🇦XTSX.ARCHCanadaHealthcare
PriceCA$0.84-0.02 (-2.33%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 2
- Medium: 2
- Low: 0
Financial leverage: a sudden spike above its trailing quarter average
Leverage ratio: a sudden spike above its trailing quarter average
Current ratio: below the level we flag as a liquidity warning
Quick ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- TSX Venture Exchange . XTSX
- Type
- Stock
- ISIN
- CA03938C1041
- CUSIP
- 03938C104
Company
- Employees
- 0
- Headquarters
- Toronto, Canada
Market
- Shares outstanding
- 66.1M
- Market cap
- CA$55.53M
Highlights
- Market cap
- CA$55.53M
- EPS LTM
- -CA$0.04calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -23.26calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$0+100%up year on year
- Net income
- -CA$2.39M+7.2%up year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$1.83M+32.86%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Arch Biopartners Inc is a company in the healthcare sector, listed on TSX Venture Exchange (Canada) under the ticker ARCH. Its market capitalisation is CA$55.53M, from 66.1M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$0.39 and CA$1.45, and the last close of CA$0.84 sits 42% of the way up that range. The company is headquartered in Toronto, Canada.
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops AB569 for treating antibiotic-resistant bacterial infections and as a topical treatment for wounds; and Borg, a peptide-solid surface interface, which are binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Arch Biopartners Inc. is based in Toronto, Canada.